The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 20-21, 2009, Pages 1907-1914

  Delahunty, Tom ^a   Bushman, Lane ^a   Robbins, Brian ^a   Fletcher, Courtney V ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Emtricitabine (FTC); Isotopic internal standards (IS); LC MS MS; Pharmacokinetics; Selective reaction monitoring (SRM); Tenofovir (TFV); Tenofovir disoproxil fumarate (TDF)

Indexed keywords

EMTRICITABINE (FTC); ISOTOPIC INTERNAL STANDARDS (IS); LC/MS/MS; SELECTIVE REACTION MONITORING (SRM); TENOFOVIR (TFV); TENOFOVIR DISOPROXIL FUMARATE (TDF);

ACIDS; CENTRIFUGATION; DRUG DOSAGE; DRUG PRODUCTS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; IONS; ISOTOPES; MASS SPECTROMETRY; PHARMACOKINETICS; RELUCTANCE MOTORS; STANDARDS;

PLASMAS;

ACETIC ACID; ACETONITRILE; ADENINE; CARBON 13; CYTOSINE; EDETIC ACID; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ION; ISOTOPE; NITROGEN 15; TENOFOVIR; TENOFOVIR DISOPROXIL; TRIFLUOROACETIC ACID;

ARTICLE; CENTRIFUGATION; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY; PLASMA; PRECURSOR; PRIORITY JOURNAL; SEPARATION TECHNIQUE; STANDARD; VALIDATION STUDY;

ADENINE; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DRUG STABILITY; HUMANS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 67049172869     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.05.029     Document Type: Article

References (14)

1. Blum M., Chittick G., Begley J., and Zong J. J. Clin. Pharmacol. 47 (2007) 751-759
2. Gallant J., Dejesus E., Arribas J., Pozniak A., Gazzard B., Campo R., Lu B., McColl D., Chuck S., Enejosa J., Toole J., and Cheng A. N. Engl. J. Med. 354 (2006) 251-260
3. Chi B., Sinkala M., Mbewe F., Cantrell R., Kruse G., Chintu N., Aldrovandi G., Stringer E., Kankasa C., Safrit J., and Stringer J. Lancet 370 (2007) 1698-1705
4. Delahunty T., Bushman L., and Fletcher C.V. J. Chromatogr. B 830 (2006) 6-12
5. Kiser J., Carten M., Aquilante C., Anderson P., Wolfe P., King T., Delahunty T., Bushman L., and Fletcher C.V. Clin. Pharm. Ther. 83 (2008) 265-272
6. Rezk N., Crutchley R., and Kashuba A. J. Chromatogr. B 822 (2005) 201-208
7. Sparidans R., Prins J., Schellens J., and Beijnen J. Biomed. Chromatogr. 21 (2007) 621-627
8. Matuszewski M., Constanzer C., and Chavez-Eng M. Anal. Chem. 75 (2003) 3019-3030
9. Delahunty T., Bushman L., and Fletcher C. Clin. Chem. 53 (2007) A100
10. Gomes N., Vaidya V., Putage A., Joshi S., and Parekh S. J. Pharm. Biomed. Anal. 48 (2008) 918-926
11. D'Avolio A., Sciandra M., Siccardi M., Baietto L., Gonzalez de Requena D., Bonora S., and Di Perri G. J. Chromatogr. Sci. 46 (2008) 524-528
12. Nirogi R., Bhyrapuneni G., Kandikere V., Mudigonda K., Komarneni P., Aleti R., and Mukkanti K. Biomed. Chromatogr. (2008) 1-11
13. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation (2001), US Department of Health and Human Services, CDER and CVM, Rockville, MD. www.fda.gov/cder/guideance/index.htm
14. Gehrig A., Mikus G., Haefeli W., and Burhenne J. Rapid Commun. Mass Spectrom. 21 (2007) 2704-2716